Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000077.xml
Download PDF
Semin Thromb Hemost 2012; 38(07): 652-660
DOI: 10.1055/s-0032-1326781
DOI: 10.1055/s-0032-1326781
Perioperative Management of Patients Having Noncardiac Surgery Who Are Receiving Anticoagulant or Antiplatelet Therapy: An Evidence-Based but Practical Approach
Further Information
Publication History
Publication Date:
03 October 2012 (online)
Abstract
Patients receiving anticoagulant or antiplatelet therapy who require noncardiac surgery represent a common yet challenging clinical problem. Clinicians must balance the risk of thromboembolic and major adverse cardiovascular events that are associated with interrupting these therapies, against the risk of bleeding from continuing these drugs in the perioperative period. Identifying patients at highest risk for such complications requires particular attention to the role of bridging therapy and the optimal timing and duration of drug withdrawal and resumption with surgery. Patients with coronary stents represent a population that requires specific considerations, due to the added risk and significant mortality associated with perioperative stent thrombosis. Minimizing this risk is dependent on several patient- and stent-specific factors. This review provides clinicians with a summary of the available evidence to facilitate a practical approach to the management of these patients while highlighting the need for continued research in this field.
-
References
- 1 Weiser TG, Regenbogen SE, Thompson KD , et al. An estimation of the global volume of surgery: a modelling strategy based on available data. Lancet 2008; 372 (9633) 139-144
- 2 Spyropoulos AC, Bauersachs RM, Omran H, Cohen M. Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapy. Curr Med Res Opin 2006; 22 (6) 1109-1122
- 3 Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137 (2) 263-272
- 4 Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285 (22) 2864-2870
- 5 Kaatz S, Douketis JD, Zhou H, Gage BF, White RH. Risk of stroke after surgery in patients with and without chronic atrial fibrillation. J Thromb Haemost 2010; 8 (5) 884-890
- 6 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138 (5) 1093-1100
- 7 Omran H, Bauersachs R, Rübenacker S, Goss F, Hammerstingl C. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost 2012; 108 (1) 65-73
- 8 Douketis JD, Spyropoulos AC, Spencer FA , et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 suppl.) 326-350
- 9 Nematulla A, Alabousi A, Blanas N, Douketis JD, Sutherland SE. Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis. J Can Dent Assoc 2009; 75 (1) 41
- 10 Alcalay J. Cutaneous surgery in patients receiving warfarin therapy. Dermatol Surg 2001; 27 (8) 756-758
- 11 Billingsley EM, Maloney ME. Intraoperative and postoperative bleeding problems in patients taking warfarin, aspirin, and nonsteroidal antiinflammatory agents. A prospective study. Dermatol Surg 1997; 23 (5) 381-383 , discussion 384–385
- 12 Jamula E, Anderson J, Douketis JD. Safety of continuing warfarin therapy during cataract surgery: a systematic review and meta-analysis. Thromb Res 2009; 124 (3) 292-299
- 13 Kallio H, Paloheimo M, Maunuksela EL. Haemorrhage and risk factors associated with retrobulbar/peribulbar block: a prospective study in 1383 patients. Br J Anaesth 2000; 85 (5) 708-711
- 14 Palareti G, Legnani C. Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet 1996; 30 (4) 300-313
- 15 Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005; 44 (12) 1227-1246
- 16 White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 1995; 122 (1) 40-42
- 17 Steib A, Barre J, Mertes M , et al. Can oral vitamin K before elective surgery substitute for preoperative heparin bridging in patients on vitamin K antagonists?. J Thromb Haemost 2010; 8 (3) 499-503
- 18 Dunn A. Perioperative management of oral anticoagulation: when and how to bridge. J Thromb Thrombolysis 2006; 21 (1) 85-89
- 19 Kovacs MJ, Kearon C, Rodger M , et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004; 110 (12) 1658-1663
- 20 Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004; 164 (12) 1319-1326
- 21 Spyropoulos AC, Turpie AG, Dunn AS , et al; REGIMEN Investigators. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost 2006; 4 (6) 1246-1252
- 22 Spandorfer JM, Lynch S, Weitz HH, Fertel S, Merli GJ. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol 1999; 84 (4) 478-480 , A10
- 23 Constans M, Santamaria A, Mateo J, Pujol N, Souto JC, Fontcuberta J. Low-molecular-weight heparin as bridging therapy during interruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy. Int J Clin Pract 2007; 61 (2) 212-217
- 24 Pengo V, Cucchini U, Denas G , et al; Italian Federation of Centers for the Diagnosis of Thrombosis and Management of Antithrombotic Therapies (FCSA). Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation 2009; 119 (22) 2920-2927
- 25 Malato A, Saccullo G, Lo Coco L , et al. Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin. J Thromb Haemost 2010; 8 (1) 107-113
- 26 Douketis JD, Woods K, Foster GA, Crowther MA. Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost 2005; 94 (3) 528-531
- 27 Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost 2007; 5 (11) 2211-2218
- 28 Devereaux PJ, Chan M, Eikelboom J. Major vascular complications in patients undergoing non-cardiac surgery: magnitude of the problem, risk prediction, surveillance, and prevention. In: Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ, , editors. Evidence based Cardiology. 3rd ed. West Sussex, UK: Wiley-Blackwell; 2010: 47-62
- 29 Priebe HJ. Triggers of perioperative myocardial ischaemia and infarction. Br J Anaesth 2004; 93 (1) 9-20
- 30 Devereaux PJ, Goldman L, Cook DJ, Gilbert K, Leslie K, Guyatt GH. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ 2005; 173 (6) 627-634
- 31 Yun AJ, Lee PY, Bazar KA. Can thromboembolism be the result, rather than the inciting cause, of acute vascular events such as stroke, pulmonary embolism, mesenteric ischemia, and venous thrombosis?: a maladaptation of the prehistoric trauma response. Med Hypotheses 2005; 64 (4) 706-716
- 32 Hjemdahl P, Larsson PT, Wallén NH. Effects of stress and beta-blockade on platelet function. Circulation 1991; 84 (6, Suppl) VI44-VI61
- 33 Beving H, Zhao C, Albåge A, Ivert T. Abnormally high platelet activity after discontinuation of acetylsalicylic acid treatment. Blood Coagul Fibrinolysis 1996; 7 (1) 80-84
- 34 Fatah K, Beving H, Albåge A, Ivert T, Blombäck M. Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient?. Eur Heart J 1996; 17 (9) 1362-1366
- 35 Biondi-Zoccai GG, Lotrionte M, Agostoni P , et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006; 27 (22) 2667-2674
- 36 Mantz J, Samama CM, Tubach F , et al; Stratagem Study Group. Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events after elective non-cardiac surgery: the multicentre, randomized, blinded, placebo-controlled, STRATAGEM trial. Br J Anaesth 2011; 107 (6) 899-910
- 37 Oscarsson A, Gupta A, Fredrikson M , et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth 2010; 104 (3) 305-312
- 38 Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355 (9212) 1295-1302
- 39 Burger W, Chemnitius JM, Kneissl GD, Rücker G. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta-analysis. J Intern Med 2005; 257 (5) 399-414
- 40 Palmer JD, Sparrow OC, Iannotti F. Postoperative hematoma: a 5-year survey and identification of avoidable risk factors. Neurosurgery 1994; 35 (6) 1061-1064 , discussion 1064–1065
- 41 Reddy PR, Vaitkus PT. Risks of noncardiac surgery after coronary stenting. Am J Cardiol 2005; 95 (6) 755-757
- 42 Ernst A, Eberhardt R, Wahidi M, Becker HD, Herth FJ. Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans. Chest 2006; 129 (3) 734-737
- 43 Sørensen R, Hansen ML, Abildstrom SZ , et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374 (9706) 1967-1974
- 44 Roger VL, Go AS, Lloyd-Jones DM , et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation 2011; 123 (4) e18-e209
- 45 To AC, Armstrong G, Zeng I, Webster MWI. Noncardiac surgery and bleeding after percutaneous coronary intervention. Circ Cardiovasc Interv 2009; 2 (3) 213-221
- 46 Vicenzi MN, Meislitzer T, Heitzinger B, Halaj M, Fleisher LA, Metzler H. Coronary artery stenting and non-cardiac surgery—a prospective outcome study. Br J Anaesth 2006; 96 (6) 686-693
- 47 Compton PA, Zankar AA, Adesanya AO, Banerjee S, Brilakis ES. Risk of noncardiac surgery after coronary drug-eluting stent implantation. Am J Cardiol 2006; 98 (9) 1212-1213
- 48 Rabbitts JA, Nuttall GA, Brown MJ , et al. Cardiac risk of noncardiac surgery after percutaneous coronary intervention with drug-eluting stents. Anesthesiology 2008; 109 (4) 596-604
- 49 Fox KA, Mehta SR, Peters RJ , et al; Clopidogrel in unstable angina to prevent recurrent ischemic events trial—benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome—the clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial. Circulation 2004; 110 (10) 1202-1208
- 50 Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001; 88 (6) 787-800
- 51 Bell AD, Roussin A, Cartier R , et al; Canadian Cardiovascular Society. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. Can J Cardiol 2011; 27 (Suppl A) S1-S59
- 52 Ong ATL, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45 (12) 2088-2092
- 53 Iakovou I, Schmidt T, Bonizzoni E , et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293 (17) 2126-2130
- 54 Nuttall GA, Brown MJ, Stombaugh JW , et al. Time and cardiac risk of surgery after bare-metal stent percutaneous coronary intervention. Anesthesiology 2008; 109 (4) 588-595
- 55 Abualsaud AO, Eisenberg MJ. Perioperative management of patients with drug-eluting stents. JACC Cardiovasc Interv 2010; 3 (2) 131-142
- 56 Cruden NL, Harding SA, Flapan AD , et al; Scottish Coronary Revascularisation Register Steering Committee. Previous coronary stent implantation and cardiac events in patients undergoing noncardiac surgery. Circ Cardiovasc Interv 2010; 3 (3) 236-242
- 57 Thiele T, Sümnig A, Hron G , et al. Platelet transfusion for reversal of dual antiplatelet therapy in patients requiring urgent surgery: a pilot study. J Thromb Haemost 2012; 10 (5) 968-971
- 58 Madan GA, Madan SG, Madan G, Madan AD. Minor oral surgery without stopping daily low-dose aspirin therapy: a study of 51 patients. J Oral Maxillofac Surg 2005; 63 (9) 1262-1265
- 59 Kargi E, Babuccu O, Hosnuter M, Babuccu B, Altinyazar C. Complications of minor cutaneous surgery in patients under anticoagulant treatment. Aesthetic Plast Surg 2002; 26 (6) 483-485
- 60 Lumme P, Laatikainen LT. Risk factors for intraoperative and early postoperative complications in extracapsular cataract surgery. Eur J Ophthalmol 1994; 4 (3) 151-158
- 61 Kumar N, Jivan S, Thomas P, McLure H. Sub-Tenon's anesthesia with aspirin, warfarin, and clopidogrel. J Cataract Refract Surg 2006; 32 (6) 1022-1025
- 62 Patrono C, Baigent C, Hirsh J , et al. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133 (6 Suppl) 199-233
- 63 Bolsin S, Conroy M, Osborne C. Tirofiban 'bridging' therapy for patients with drug-eluting stents undergoing non-cardiac surgery. Br J Anaesth 2010; 104 (6) 779-780 , author reply 779–780
- 64 Angiolillo DJ, Firstenberg MS, Price MJ , et al; BRIDGE Investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012; 307 (3) 265-274